Key result
Ex vivo salvianolic acid A cuts ADP-induced platelet activation ~88% and inhibits aggregation in ACS.
Why the study?
To investigate the effect of salvianolic acid A (SAA) on platelets in patients with acute coronary syndrome and explore its potential mechanism of action.
Does ex vivo treatment with salvianolic acid A reduce platelet aggregation and activation in patients with acute coronary syndrome?
Does ex vivo treatment with salvianolic acid A reduce platelet aggregation and activation in patients with acute coronary syndrome?
Absolute Event Rate: 9.58% vs 78.42%
p-value: p=<0.05
Ex vivo treatment with salvianolic acid A significantly reduces platelet aggregation and activation in patients with acute coronary syndrome, suggesting potential therapeutic value as an antiplatelet agent.
Ex vivo SAA effects on ACS platelets are hypothesis-generating; in vivo trials needed before any clinical consideration.
BACKGROUND: The acute blockage in coronary arteries further causes acute coronary syndrome (ACS). There are 2 main factors implicated in the activation and aggregation of platelets. However, this present study aimed to investigate the effect of salvianolic acid A (SAA) on the platelets in patients with ACS and explore its potential mechanism of action. METHODS: The impact of SAA on platelets under different stimulation conditions was studied using flow cytometry and platelet aggregation detection techniques. RESULTS: The results demonstrated that in 40 ACS patients, ex vivo treatment of platelets with SAA (0.1 mg/ml) significantly reduced aggregation and activation. Intriguingly, we found no significant difference between the 3 types of ACS patients in the antiplatelet effect of SAA. Moreover, the results indicated that C-reactive protein, alanine aminotransferase, C-reactive protein-to-albumin ratio, total cholesterol, and low-density lipoprotein levels were negatively correlated with the anti-platelet effect of SAA in ACS patients and that a history of smoking may reduce the anti-platelet effect of SAA in the same group. CONCLUSION: In summary, the above findings of this study highlight the therapeutic potential of SAA against platelets in patients with ACS, providing new insights into clinical treatment and experimental research.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied Acute coronary syndrome (n=40). Salvianolic acid A vs. Physiological saline (vehicle control) was evaluated on ADP-induced PAC-1 expression (platelet activation) (p=<0.05). Ex vivo treatment with salvianolic acid A significantly reduced ADP-induced PAC-1 expression from 78.42% to 9.58% and inhibited platelet aggregation in patients with acute coronary syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: